Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,862 across all filing types
Latest filing 2023-10-30 M&A Activity
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
231030 GLPG Press Release Alfasigma_Final_NL.pdf
M&A Activity Classification · 99% confidence The document is a press release dated October 30, 2023, announcing a definitive agreement (Intentieverklaring/Letter of Intent) for Galapagos to transfer its Jyseleca® activities to Alfasigma. It details the financial terms (€50M upfront, milestones, royalties), expected cost savings (€150M-€200M annually), and associated organizational restructuring (job reductions). It also discusses the modification of a related agreement with Gilead Sciences concerning filgotinib. This type of announcement, detailing a major corporate transaction (divestiture/asset transfer) and its financial implications, fits best under 'Capital/Financing Update' (CAP) as it fundamentally alters the company's structure and asset base, or potentially 'Regulatory Filings' (RNS) if it were a mandatory disclosure without a better fit. However, given the focus on a major transaction involving asset transfer and significant financial restructuring, 'CAP' is the most specific fit among the provided options, as it relates to capital structure changes and major corporate financing/divestiture activities. It is not an Earnings Release (ER), Interim Report (IR), or Annual Report (10-K). Since it is a detailed announcement of a transaction rather than just a notice of publication, RPA/RNS is less appropriate than CAP.
2023-10-30 Dutch
Galapagos appoints Simon Sturge to its Board of Directors
Board/Management Information Classification · 99% confidence The document is a press release announcing a change in the company's governing body: the appointment of Mr. Simon Sturge to the Board of Directors and the resignation of Dr. Mary Kerr. This content directly aligns with the definition of 'Board/Management Information' (MANG), which covers announcements of changes in the company's board of directors or senior management. The document is not a full financial report (10-K or IR), an earnings release (ER), or a proxy statement (DEF 14A/PSI).
2023-09-20 English
Galapagos appoints Simon Sturge to its Board of Directors
Board/Management Information Classification · 99% confidence The document is a press release announcing a change in the company's leadership structure: the appointment of a new Non-Executive Independent Director (Mr. Simon Sturge) and the departure of another (Dr. Mary Kerr). This content directly aligns with the definition of 'Board/Management Information' (MANG), which covers announcements of changes in the company's board of directors or senior management. The document is not a full financial report (10-K, IR), an earnings release (ER), or a proxy statement (DEF 14A/PSI).
2023-09-20 English
6-K Filing
Regulatory Filings
2023-09-20 English
6-K Filing
Regulatory Filings
2023-08-30 English
Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus
Regulatory Filings Classification · 95% confidence The document is a press release announcing a specific corporate event: the start of a Phase 2 clinical study for a drug candidate (GLPG3667) in patients with systemic lupus erythematosus (SLE). It contains key highlights, contact information for media/investors, and standard forward-looking statements typical of such announcements. This format—a brief announcement of a scientific/clinical milestone—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a full financial report (10-K, IR), a transcript (CT), or a presentation (IP), and it is a direct announcement of a significant operational update, it fits best under the general category for corporate news releases that aren't strictly financial results or dividend notices. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a press release detailing clinical trial progress, although 'ER' often covers operational updates alongside earnings. However, since this is purely clinical trial news, RNS is safer than ER, which usually implies financial results. Upon review, RNS is the best fit for general, non-financial regulatory/operational news releases that don't fit a more specific category like LTR or MANG.
2023-08-29 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.